Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Biol Chem
2009 Mar 27;28413:8633-42. doi: 10.1074/jbc.M807860200.
Show Gene links
Show Anatomy links
Estrogen Receptor {alpha} Enhances the Rate of Oxidative DNA Damage by Targeting an Equine Estrogen Catechol Metabolite to the Nucleus.
Wang Z
,
Wijewickrama GT
,
Peng KW
,
Dietz BM
,
Yuan L
,
van Breemen RB
,
Bolton JL
,
Thatcher GR
.
???displayArticle.abstract???
Exposure to estrogens increases the risk of breast and endometrial cancer. It is proposed that the estrogen receptor (ER) may contribute to estrogen carcinogenesis by transduction of the hormonal signal and as a "Trojan horse" concentrating genotoxic estrogen metabolites in the nucleus to complex with DNA, enhancing DNA damage. 4-Hydroxyequilenin (4-OHEN), the major catechol metabolite of equine estrogens present in estrogen replacement formulations, autoxidizes to a redox-cycling quinone that has been shown to cause DNA damage. 4-OHEN was found to be an estrogen of nanomolar potency in cell culture using a luciferase reporter assay and, using a chromatin immunoprecipitation assay, was found to activate ERalpha binding to estrogen-responsive genes in MCF-7 cells. DNA damage was measured in cells by comparing ERalpha(+) versus ERalpha(-) cells and 4-OHEN versus menadione, a reactive oxygen species (ROS)-generating, but non-estrogenic, quinone. 4-OHEN selectively induced DNA damage in ERalpha(+) cells, whereas menadione-induced damage was not dependent on cellular ER status. The rate of 4-OHEN-induced DNA damage was significantly enhanced in ERalpha(+) cells, whereas ER status had no effect on the rate of menadione-induced damage. Imaging of ROS induced by 4-OHEN showed accumulation selective for the nucleus of ERalpha(+) cells within 5 min, whereas in ERalpha(-) or menadione-treated cells, no selectivity was observed. These data support ERalpha acting as a Trojan horse concentrating 4-OHEN in the nucleus to accelerate the rate of ROS generation and thereby amplify DNA damage. The Trojan horse mechanism may be of general importance beyond estrogen genotoxins.
Bocchinfuso,
A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha.
1999, Pubmed
Bocchinfuso,
A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha.
1999,
Pubmed
Bocchinfuso,
Mammary gland development and tumorigenesis in estrogen receptor knockout mice.
1997,
Pubmed
Bolton,
Role of quinoids in estrogen carcinogenesis.
1998,
Pubmed
Bolton,
Potential mechanisms of estrogen quinone carcinogenesis.
2008,
Pubmed
Bolton,
Quinoids, quinoid radicals, and phenoxyl radicals formed from estrogens and antiestrogens.
2002,
Pubmed
Burczynski,
Genotoxic polycyclic aromatic hydrocarbon ortho-quinones generated by aldo-keto reductases induce CYP1A1 via nuclear translocation of the aryl hydrocarbon receptor.
2000,
Pubmed
Carroll,
Estrogen receptor target gene: an evolving concept.
2006,
Pubmed
Cavalieri,
Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators.
1997,
Pubmed
Cavalieri,
Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention.
2006,
Pubmed
Chang,
Activation of estrogen receptor-mediated gene transcription by the equine estrogen metabolite, 4-methoxyequilenin, in human breast cancer cells.
2007,
Pubmed
Chen,
The equine estrogen metabolite 4-hydroxyequilenin causes DNA single-strand breaks and oxidation of DNA bases in vitro.
1998,
Pubmed
Chen,
A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines.
2000,
Pubmed
Cho,
Differential regulation of gene expression by estrogen in estrogen growth-independent and -dependent MCF-7 human breast cancer cell sublines.
1991,
Pubmed
Cobleigh,
Hormone replacement therapy and high S phase in breast cancer.
1999,
Pubmed
Colditz,
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
1995,
Pubmed
Collins,
The comet assay: what can it really tell us?
1997,
Pubmed
Embrechts,
Detection of estrogen DNA-adducts in human breast tumor tissue and healthy tissue by combined nano LC-nano ES tandem mass spectrometry.
2003,
Pubmed
Feigelson,
Estrogens and breast cancer.
1996,
Pubmed
Fischer,
Increased formation of micronuclei after hormonal stimulation of cell proliferation in human breast cancer cells.
2001,
Pubmed
Flötotto,
Hormones and hormone antagonists: mechanisms of action in carcinogenesis of endometrial and breast cancer.
2001,
Pubmed
Gaikwad,
The molecular etiology of breast cancer: evidence from biomarkers of risk.
2008,
Pubmed
Glass,
Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
2007,
Pubmed
Grodstein,
Postmenopausal hormone therapy and mortality.
1997,
Pubmed
Han,
Microsome-mediated 8-hydroxylation of guanine bases of DNA by steroid estrogens: correlation of DNA damage by free radicals with metabolic activation to quinones.
1995,
Pubmed
Harrington,
Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action.
2006,
Pubmed
Henderson,
Hormonal carcinogenesis.
2000,
Pubmed
Hua,
Comparison of negative and positive ion electrospray tandem mass spectrometry for the liquid chromatography tandem mass spectrometry analysis of oxidized deoxynucleosides.
2001,
Pubmed
Jefcoate,
Tissue-specific synthesis and oxidative metabolism of estrogens.
2000,
Pubmed
Kerlikowske,
Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.
2007,
Pubmed
Key,
Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.
2002,
Pubmed
LeBel,
Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress.
1992,
Pubmed
Li,
Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: relation to hormonal activity and cell proliferation.
1995,
Pubmed
Liehr,
Is estradiol a genotoxic mutagenic carcinogen?
2000,
Pubmed
Liu,
Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
2003,
Pubmed
Liu,
Oxidative DNA damage induced by equine estrogen metabolites: role of estrogen receptor alpha.
2002,
Pubmed
Lupulescu,
Estrogen use and cancer incidence: a review.
1995,
Pubmed
Mitra,
A rationally designed genotoxin that selectively destroys estrogen receptor-positive breast cancer cells.
2002,
Pubmed
Mobley,
Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer.
2004,
Pubmed
Mueck,
Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition.
2003,
Pubmed
Nandi,
Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis.
1995,
Pubmed
Nutter,
DNA strand scission and free radical production in menadione-treated cells. Correlation with cytotoxicity and role of NADPH quinone acceptor oxidoreductase.
1992,
Pubmed
Okamoto,
Oxidative DNA damage in XPC-knockout and its wild mice treated with equine estrogen.
2008,
Pubmed
Pedram,
Nature of functional estrogen receptors at the plasma membrane.
2006,
Pubmed
Perillo,
DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression.
2008,
Pubmed
Pisha,
Evidence that a metabolite of equine estrogens, 4-hydroxyequilenin, induces cellular transformation in vitro.
2001,
Pubmed
Ravdin,
The decrease in breast-cancer incidence in 2003 in the United States.
2007,
Pubmed
Rosenberg,
Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
2006,
Pubmed
Rossouw,
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
2002,
Pubmed
Service,
New role for estrogen in cancer?
1998,
Pubmed
Shang,
Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription.
2000,
Pubmed
Sharma,
Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents.
2004,
Pubmed
Shen,
Bioreductive activation of catechol estrogen-ortho-quinones: aromatization of the B ring in 4-hydroxyequilenin markedly alters quinoid formation and reactivity.
1997,
Pubmed
Shen,
Alkylation of 2'-deoxynucleosides and DNA by the Premarin metabolite 4-hydroxyequilenin semiquinone radical.
1998,
Pubmed
Shumaker,
Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
2003,
Pubmed
Singh,
A simple technique for quantitation of low levels of DNA damage in individual cells.
1988,
Pubmed
Stopper,
Increased cell proliferation is associated with genomic instability: elevated micronuclei frequencies in estradiol-treated human ovarian cancer cells.
2003,
Pubmed
Ubezio,
Flow cytometric detection of hydrogen peroxide production induced by doxorubicin in cancer cells.
1994,
Pubmed
Vogel,
Clinical management of women at increased risk for breast cancer.
1993,
Pubmed
Yager,
Estrogen carcinogenesis in breast cancer.
2006,
Pubmed
Zhang,
The major metabolite of equilin, 4-hydroxyequilin, autoxidizes to an o-quinone which isomerizes to the potent cytotoxin 4-hydroxyequilenin-o-quinone.
1999,
Pubmed
Zhang,
Estrogen carcinogenesis: specific identification of estrogen-modified nucleobase in breast tissue from women.
2008,
Pubmed
Zhang,
Equine estrogen metabolite 4-hydroxyequilenin induces DNA damage in the rat mammary tissues: formation of single-strand breaks, apurinic sites, stable adducts, and oxidized bases.
2001,
Pubmed
Zumoff,
Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy.
1998,
Pubmed
